Adenosine

Evidence Level: L5

Predicted Indications: 1

Adenosine

Pharmacist Assessment Report

Adenosine: adenosine receptor agonist (antiarrhythmic) → obsolete bundle branch block

One-Sentence Summary

Adenosine is an injectable drug that acts on adenosine receptors and slows conduction through the heart’s atrioventricular node. The TxGNN model predicts it may be effective for obsolete bundle branch block, but no clinical trials and no publications currently support this direction. The term “obsolete” marks a deprecated disease label, so this prediction may be an artifact of the disease ontology rather than a genuine therapeutic signal.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	obsolete bundle branch block
TxGNN Prediction Score	0.9994
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. In general, adenosine is known to slow conduction through the atrioventricular (AV) node and is used diagnostically and therapeutically in rhythm disturbances involving rapid heart rates.

The model gives this prediction a very high score (0.9994), but the score reflects a computational pattern only. No clinical trial or publication was found that studies adenosine in bundle branch block. Because the disease term is flagged as obsolete, the prediction may reflect a deprecated ontology entry. No direct therapeutic rationale is evident, and a drug that slows cardiac conduction could even worsen conduction disturbances. The mechanistic link is therefore weak and should not be treated as support for use.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02457474	ADENOSINE INJECTION	Injection	Not recorded in local data
02457482	ADENOSINE INJECTION	Injection	Not recorded in local data
02267659	ADENOSINE INJECTION	Injection	Not recorded in local data

Safety Considerations

Drug Interactions: 100 interactions were found in the interaction screening. Examples of those rated Major: cisapride, dolasetron and papaverine. Examples rated Moderate: famotidine, clarithromycin, granisetron, levofloxacin, ondansetron and palonosetron. Several of these (cisapride, dolasetron, granisetron, ondansetron, palonosetron, clarithromycin, levofloxacin) are agents that can affect cardiac rhythm, which deserves particular attention in a conduction-disorder setting.
Please also refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone, with no supporting trials or publications, and the disease term is obsolete. Adenosine’s effect on cardiac conduction raises a plausible safety concern rather than a benefit in bundle branch block.

To proceed, the following is needed:

Confirmation of whether the disease term maps to a current, clinically meaningful condition
A clear mechanistic rationale and preclinical or clinical evidence in the relevant condition
Package insert warnings and contraindications from Health Canada for safety screening
Mechanism of action data for adenosine
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.